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Background: Alzheimer’s disease and related disorders are characterized by cognitive impairment associated with
behavioral and psychological symptoms of dementia. These symptoms have significant consequences for both the
patient and his family environment. While risk factors for behavioral disorders have been identified in several
studies, few studies have focused on the evolution of these disorders. Moreover, it is important to identify factors
linked to the long-term evolution of behavioral disorders, as well as patients’ and caregivers’ quality of life. Our
purpose is to present the methodology of the EVITAL study, which primary objective is to determine the factors
associated with the evolution of behavioral disorders among patients with Alzheimer’s disease and related disorders
during the year following their hospitalization in cognitive and behavioral units. Secondary objectives were 1) to
assess the factors related to the evolution of behavioral disorders during hospitalization in cognitive and behavioral
units; 2) to identify the factors linked to patients’ and caregivers’ quality of life, as well as caregivers’ burden; 3) to
assess the factors associated with rehospitalization of the patients for behavioral disorders in the year following their
hospitalization in cognitive and behavioral units.
Method/Design: A multicenter, prospective cohort of patients with Alzheimer’s disease and related disorders as
well as behavioral disorders who are hospitalized in cognitive and behavioral units.
The patients will be included in the study for a period of 24 months and followed-up for 12 months. Socio-demographic
and environmental data, behavioral disorders, medications, patients’ and caregivers’ quality of life as well as caregivers’
burden will be assessed throughout hospitalization in cognitive and behavioral units. Follow-up will be performed at
months 3, 6 and 12 after hospitalization. Socio-demographic and environmental data, behavioral disorders, medications,
patients’ and caregivers’ quality of life, unplanned rehospitalization as well as caregivers’ burden will also be assessed at
each follow-up interview.
Discussion: The present study should help better identify the factors associated with reduction or stabilization of the
behavioral and psychological symptoms of dementia in patients with Alzheimer’s disease. It could therefore help
clinicians to better manage these symptoms.
Trial registration: Clinical Trials NCT01901263. Registered July 9, 2013.
Keywords: Alzheimer’s disease and related disorders, Behavioural and psychological symptoms of dementia,
Quality of life* Correspondence: elodie.pongan@gmail.com
1Service de Neurologie, CM2R, CHU de Saint Etienne, Hôpital Nord, Avenue
Albert Raimond, 42055 Saint Etienne, France
2Hospices civils de Lyon, CM2R, Hôpital gériatrique des Charpennes, 27 rue
Gabriel Péri, 69100 Villeurbanne, France
Full list of author information is available at the end of the article
© 2014 Pongan et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Pongan et al. BMC Psychiatry 2014, 14:308 Page 2 of 6
http://www.biomedcentral.com/1471-244X/14/308Background
Alzheimer’s disease and related disorders (ADRD) are
characterized by cognitive impairment associated with
behavioral and psychological symptoms of dementia
(BPSD) [1]. The BPSD are common in ADRD and often
associated with one another [2-4]. They may occur at all
stages of the disease and worsen with cognitive decline.
Besides apathy and depression, which are frequent
during the early/middle stages of the disease (40 to 60%
of patients), other BPSD such as agitation (30%), irrit-
ability (30%), delusions (10 to 20%), aberrant motor be-
havior (15 to 30%) and hallucinations (6 to 10%) [5,6]
can be very upsetting for both the patient and the
caregiver.
BPSD have significant consequences for both the pa-
tient and the family as they may lead to difficulties in
activities of daily living (ADL) [3] and interfere with
patients’ quality of life (QoL) [7]. Moreover, they are as-
sociated with faster cognitive impairment [8]. They in-
crease the risk of hospitalization as well as developing
other complications of dementia. Furthermore, they can
lead to an increase in caregivers’ health problems and a
decrease in their QoL [7]. Studies have shown that the
severity of BPSD was connected with the burden and
psychological state of caregivers [9-11]. All these conse-
quences result in increased health expenditures [12]. Fi-
nally, they can precipitate nursing home placement
regardless of cognitive impairment [13,14].
Identification of BPSD is important to optimize ADRD
patient management. Current treatment strategies consist
in non-drug therapies and subsequently pharmacological
treatments, including specific treatment for Alzheimer’s
disease. A previous study showed that the management of
BPSD can reduce the rate of home nursing placement as
well as caregivers’ burden and increase a QoL [15]. The
unpredictable occurrence of these symptoms and difficulty
to stabilize them may lead to crises. The French Alzheimer
Plan 2008–2012 has provided specific hospital units called
cognitive and behavioral units (CBUs). These units are
intended for patients with ADRD and productive be-
havior disorders. While risk factors for BPSD have
been identified in several studies, few studies have fo-
cused on the evolution of these symptoms. To our
knowledge, only two studies focused on BPSD evolu-
tion in patients admitted to CBUs. The first one
assessed short-term BPSD evolution from CBU admis-
sion to discharge [16]. The second showed a favorable
effect of hospitalization in the CBU on BPSD at hos-
pital discharge and 15 days after discharge [17]. Be-
yond the assessment of the short-term BPSD evolution
during hospitalization in CBUs, it would be important
to identify factors that are linked to the long-term
evolution of BPSD, as well as patients’ and caregivers’
QoL. The EVITAL study was designed to assess thesequestions. The purpose of this paper is to provide the
methodology of the EVITAL study.
Study objectives
Primary objective
– To identify the factors associated with the long-term
evolution of BPSD among patients with ADRD
during the year following their hospitalization in
the CBU.
Secondary objectives
– To assess the factors related to the reduction of
BPSD during hospitalization in CBUs.
– To identify the factors linked to patients’ and
caregivers’ QoL, and caregivers’ burden.
– To assess the factors associated with
rehospitalization of the patients for BPSD in the
year following their hospitalization in CBUs.
Methods/Design
Study design
This is a multicenter prospective cohort study.
Setting and patients
The EVITAL study will take place in the CBUs of 3 dif-
ferent hospitals located in Lyon and Saint Etienne,
France.
Inclusion criteria are: age 50 years or older, admission
to the CBU of participating centers, ADRD patients at
the dementia stage, no severe progressive or unstable
disease that may interfere with the results of the assess-
ment, and presence of a caregiver having sufficient con-
tact with the subject to be able to notice behavioral
changes.
Exclusion criteria are: patients at high risk of death
and isolated patients.
Ethics approval
The study protocol has been reviewed and approved by
an Ethics Committee (Comité de Protection des Per-
sonnes). This committee covers the ethical approval of
all three sites of our data collection. All procedures are
in accordance with the Declaration of Helsinki and the
International Conference on Harmonization (ICH) Good
Clinical Practice Guidelines.
This is a routine care research that does not require
written informed consent. An information sheet will be
given to the patient and his/her caregiver at admission
in the CBU.
Their acceptance or refusal will be noted in medical
records.
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Clinical and neuropsychological assessment
An interview and a physical examination will be per-
formed by the neurologist, geriatrician or psychiatrist in
charge of the patient. Other factors favoring BPSD such
as family situation, living conditions, previous diseases,
comorbidities, date of diagnosis, and medications will be
investigated during hospitalization.
For patients living at home, relationship with informal
and professional caregivers will be collected.
Global cognitive function will be assessed using the Mini
Mental State Examination (MMSE) [18], with scores ran-
ging from 0 to 30 points.
Hospitalization in CBUs
The following factors will be collected during hospitalization
in the CBU are: reason for hospitalization, length of stay,
type of non-drug therapies used.
Use of psychotropic drugs
Psychotropic drug use will be collected at CBU admis-
sion and discharge, and at each follow-up interview.
Dependent variables
Evaluation of BPSD
Among the scales used for exploring these disorders, the
Neuropsychiatric Inventory (NPI) [19] is commonly
used. It is often used in international studies and has
been validated in French [20].
The NPI is a questionnaire designed to collect infor-
mation on neuropsychiatric problems from patients with
brain disorders.
Behavioral disorders will be assessed during the initial
visit and each subsequent interview with the patient and
the caregiver. The short form of the Neuropsychiatric
Inventory (NPI-Q) will be used. Twelve types of neuro-
psychiatric symptoms are covered by the questionnaire:
delusions, hallucinations, agitation, depression, anxiety,
euphoria, apathy, impulsive behavior, mood swings, ab-
errant motor behavior, and eating and sleeping disorders.
For each symptom, the severity, frequency and effect on
the caregiver are assessed. A total subscale score is calcu-
lated by multiplying frequency and severity, and a global
score is generated by summing up the total scores of the
individual subscales (maximum = 144). Score measuring
the effect on the caregiver ranges from 0 to 60 points.
The “family” NPI will be given to the caregiver at
home or referent caregivers at the nursing homes. The
“healthcare team” NPI will be completed by the health-
care team during hospitalization.
Patients’ quality of life
The EuroQuol EQ-5D is used for assessing the QoL of
patients with Alzheimer’s disease. This scale includesfive areas: mobility, self-care, daily activity, physical pain,
and anxiety/depressive symptoms. A one-to-five scale is
used for each dimension. The scale will be completed
by both patient and caregiver about their own QoL. In
addition, the caregiver will answer the questions about
the patient’s QoL [21].
Caregivers’ quality of life and caregivers’ burden
The Caregiver’s Quality of Life (French abbreviation
QDVA) is a 20-item scale exploring caregiver’s QoL.
Four categories of situations are studied, according to
the angst and coping capability of caregivers. Caregiver’s
QoL and vulnerability are assessed, taking into account
the socio-demographic characteristics of both patients
and their principal caregivers, and the patients’ medical
and therapeutic data [22]. Each item is coded 5 (high
QoL) or 0 (weak QoL). A total scale score represents the
percentage of remaining QoL.
The subjective caregivers burden will be assessed using
the mini-Zarit, a validated short version of the Zarit Bur-
den Inventory, which was previously developed for rou-
tine medical care [23].
Unplanned hospitalization
The duration and reason for unplanned hospital re-
admission will be noted during the year following
discharge.
Data collection procedure
Typical schedule for a patient included in the EVITAL
protocol is given in Figure 1.
Inclusion visit
The inclusion visit will take place on the day of patient
admission in the CBU. It will be carried out by the neur-
ologist, geriatrician or psychiatrist in charge of the pa-
tient. Inclusion criteria will be validated through an
interview with the patient and his/her caregiver. During
this examination, various data will be collected: demo-
graphic and environmental data, patient’s living condi-
tions, previous diseases and comorbidities, medications
and non-drug therapies, global cognitive performance
(MMSE), BPSD (NPI and NPI-ES), caregivers’ burden
(mini-Zarit), and patients’ and caregivers’ QoL (EQ-5D,
QDVA).
End of hospitalization visit
This visit will be carried out by the neurologist, geriatri-
cian or psychiatrist in charge of the patient according to
standard practices. During this visit, the following data
will be collected: demographic and environmental data,
medications and nondrug therapies used duringhospita-
lization, and BPSD at the outcome (NPI-ES).
T0 T1 T2 T3 T4
 (1 month)    (3 months)                              (6 months)                                             (6 months)       
Figure 1 Typical schedule for a patient included in the EVITAL protocol: a summary of different stages. T0 = inclusion visit. T1 = End of
hospitalization visit. T2 = 3-month follow-up visit at home. T3 = 6-month follow-up phone call. T4 = 12-month follow-up phone call.
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A follow-up visit will be performed 3 months after dis-
charge at the patient’s residence (home or nursing
home). Follow-up phone calls will be made to caregivers
(patients’ informal caregivers at home or referent care-
givers at the nursing homes) at 6 and 12 months. During
these follow-up interviews, the following data will be
collected: demographic and environmental data, patient’s
living conditions, concomitant events, medications and
non-drug therapies, BPSD (NPI and NPI-ES), caregivers’
burden (mini-Zarit), and patients’ and caregivers’ QoL
(EQ-5D, QDVA).
Sample size
As this is a prospective, observational cohort study
that will includes a large number of specific factors to
be analyzed, there is no issue of statistical power to be
considered. However, we need a sufficient number of
participants to obtain useful outcome measures. The
three participant CBUs have a total of 300 patients per
year. We can expect that about 60% of patients will
consent to participate and meet the inclusion criteria.
Preliminary analysis made on the 50 first patients gave
an annual attrition rate of 20% during the 12-month
follow-up period, mainly due to death. All patients
who meet the inclusion criteria and are hospitalized in
the 3 participant CBUs in the span of two years will be
included in the study.
Data analysis
Univariate analysis will be first performed to assess each
study objective. Associations between the rehospitaliza-
tion or psychotropic consumption rates and independent
qualitative variables will be determined with chi2 tests.
The link between the NPI score and qualitative risk fac-
tors will be assessed using Student t tests. Multivariate
analyses will be used to take into account potential con-
founding factors.
To identify the factors associated with the evolution of
BPSD in patients with ADRD during the year following
their hospitalization in the CBU, linear regression models
and survival models will be used.
The link between management in CBUs and evolution
of BPSD during patients’ hospitalization will be assessed
with linear regression models and survival models.To identify the factors associated with patients’ and
caregivers’ QoL, and caregivers’ burden, linear regression
models and survival models will be used.
The association between changes in psychotropic drug
consumption (especially neuroleptic drugs) and the evo-
lution of BPSD will be assessed with linear regression
models and survival models.
Finally, to assess the factors associated with rehospitali-
zation of the patients for BPSD in the year following their
hospitalization in the CBU, logistic regression models will
be used.
SPSS software will be used for data analyzes.Discussion
The EVITAL project aims to better understand the fac-
tors associated with the evolution of BPSD in the year
following patient hospitalization in CBUs. It should help
us better identify the factors affecting patient’s and care-
giver’s QoL. Moreover, it could bring out factors that
modulate the risk of unplanned hospital readmission.
Finally, it should contribute to a better understanding of
the natural history of BPSD.
The originality of this project is based on three cri-
teria: the choice of the study population, duration of
follow-up and inclusion of patients from different CBUs.
Our study focuses on patients with ADRD and product-
ive BPSD requiring hospitalization in a specific unit. To
our knowledge, only two previous studies assessed the
evolution of BPSD during hospitalization in CBUs. The
results of these studies were encouraging, showing a
decrease in BPSD after patient management in CBUs.
However, both studies were limited as they only assessed
the evolution of the BPSD from patient admission to dis-
charge [16] and 15 days after discharge [17], respectively.
These studies did not give us information on the long-
term outcome of the patients after CBU management.
The present study is the first to follow patients for one
year, with assessments performed 3, 6 and 12 months
after their CBU discharge.
Moreover, these studies were conducted in only one
CBU whereas the present study includes patients from
different CBUs. The multicenter design may allow us to
include patients with various profiles, regardless of each
unit specific organization.
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both patients’ and caregivers’ quality of life [7], which is
an important point to consider. Moreover, caregivers
play a major role in helping patients stay at home, which
is one of the CBU objectives. It was showed that suc-
cessful patient management with a specific pharmaco-
logical or non- drug therapy can have a positive impact
on both patients’ and caregivers’ QoL, which are intrin-
sically connected to each other [24]. It will be interesting
to observe the evolution of their QoL as well as care-
givers’ burden after CBU management.
The assessment of patients admitted to CBUs will help
better describe and value the work done by the CBU
healthcare team. Moreover, the results of this study
could be helpful for other CBU teams to develop effect-
ive management strategies in the CBU, and to better
identify patients at high risk of increasing BPSD. The
database designed in the present research could also be
proposed to other CBUs to help them better describe
their activity with standardized data.
The EVITAL study may have several limitations. Some
patients who were living at home before their admission
in the CBU may move to a new place of residence, e.g.
in an institution, after discharge. Some scales, such as
the mini-Zarit, will be therefore used only for patients
living at home. Furthermore, the NPI will be assessed by
two different persons. However, the inter-rater reliability
of the NPI has been established [19] and the number of
patients involved should be limited, as one of the main
objectives of CBU management is to facilitate the return
to their initial place of residence after discharge.
In spite of these limitations, the management of patients
with Alzheimer’s disease or related diseases is currently a
major challenge. Therefore, it seems important to better
identify the factors associated with BPSD reduction and
patients’ and caregivers’ QoL in order to improve patient
management in the CBU and after hospitalization discharge.
The EVITAL project will help better understand these topics.
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